Next Article in Journal
First Analysis of Human Coccidioides Isolates from New Mexico and the Southwest Four Corners Region: Implications for the Distributions of C. posadasii and C. immitis and Human Groups at Risk
Next Article in Special Issue
Getting Histoplasmosis on the Map of International Recommendations for Patients with Advanced HIV Disease
Previous Article in Journal
Appressorium: The Breakthrough in Dikarya
Previous Article in Special Issue
The Fight against HIV-Associated Disseminated Histoplasmosis in the Americas: Unfolding the Different Stories of Four Centers
Open AccessReview

Histoplasmosis and Tuberculosis Co-Occurrence in People with Advanced HIV

by 1,2,*,† and 3,*,†
1
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
2
Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, School of Medicine and Health Sciences, Universidad del Rosario, 11011 Bogota, Colombia
3
Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Cayenne, 97306 Cayenne, French Guiana
*
Authors to whom correspondence should be addressed.
Contributed equally.
J. Fungi 2019, 5(3), 73; https://doi.org/10.3390/jof5030073
Received: 14 July 2019 / Revised: 5 August 2019 / Accepted: 7 August 2019 / Published: 9 August 2019
(This article belongs to the Special Issue Histoplasma and Histoplasmosis)
Distinguishing between histoplasmosis, tuberculosis (TB), and co-occurrence of disease is a frequent dilemma for clinical staff treating people with advanced Human Immunodeficiency Virus (HIV) infection. This problem is most frequently observed in clinical settings in countries where both diseases are endemic. It is also a challenge outside these endemic countries in HIV clinics that take care of patients coming from countries with endemic histoplasmosis and TB. The gold standard for diagnosis of both of these diseases is based on conventional laboratory tests (culture, histopathology and special stains). These tests have several limitations, such as lack of laboratory infrastructure for handling isolates (biosafety level 3), shortage of laboratory staff who have appropriate training and experience, variable analytical performance of tests and long turn-around time. Recently, novel rapid assays for the diagnosis of histoplasmosis and TB became available. However, this technology is not yet widely used. Mortality in immunocompromised patients, such as people with advanced HIV, is directly linked with the ability to rapidly diagnose opportunistic diseases. The aim of this review is to synthesize the main aspects of epidemiology, clinical characteristics, diagnosis and treatment of histoplasmosis/TB co-occurrence in people with advanced HIV. View Full-Text
Keywords: histoplasmosis; tuberculosis; HIV; AIDS; co-occurrence; epidemiology; diagnosis; treatment histoplasmosis; tuberculosis; HIV; AIDS; co-occurrence; epidemiology; diagnosis; treatment
Show Figures

Figure 1

MDPI and ACS Style

Caceres, D.H.; Valdes, A. Histoplasmosis and Tuberculosis Co-Occurrence in People with Advanced HIV. J. Fungi 2019, 5, 73.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop